

References for Equinox Group Schizophrenia Model (2022)

- Ayres, H., Ngo, H., & John, A. (2019). Limited changes in activities of daily life performance ability among people with schizophrenia at clinical settings and the factors moderating the changes. *Schizophrenia Research: Cognition, 16*, 29–35. <https://doi.org/10.1016/j.scog.2018.12.001>
- Bushe, C., Sniadecki, J., Bradley, A. J., & Poole Hoffmann, V. (2009). Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia [abstract]. *Journal of Psychopharmacology, 24*(7), 1001–1009. <https://doi.org/10.1177/0269881108101783>
- Chen, E., Bazargan-Hejazi, S., Ani, C., Hindman, D., Pan, D., Ebrahim, G., Shirazi, A., & Banta, J. E. (2021). Schizophrenia hospitalization in the US 2005–2014. *Medicine, 100*(15). <https://doi.org/10.1097/md.00000000000025206>
- Correll, C. U., Koblán, K. S., Hopkins, S. C., Li, Y., Heather Dworak, Goldman, R., & Loebel, A. (2021). Safety and effectiveness of ulotaront (sep-363856) in schizophrenia: Results of a 6-month, open-label extension study. *Npj Schizophrenia, 7*(63). <https://doi.org/10.1038/s41537-021-00190-z>
- Desai, P. R., Lawson, K. A., Barner, J. C., & Rascati, K. L. (2013). Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. *Journal of Pharmaceutical Health Services Research, 4*, 187–194. <https://doi.org/10.1111/jphs.12027>
- Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. *Schizophrenia Research, 152*(2-3), 450–457. <https://doi.org/10.1016/j.schres.2013.11.041>
- Fingar, K., Barrett, L., & Jiang, H. J. (2017). *Statistical Brief #230: A Comparison of All-Cause 7-Day and 30-Day Readmissions, 2014*. Healthcare Cost and Utilization Project (HCUP).
- Health Canada. (2002). Schizophrenia. In *A Report on Mental Illnesses in Canada* (pp. 49–58). Health Canada.
- Hoffer, Z. S., Roth, R. L., & Mathews, M. (2009). Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. *Psychosomatics, 50*(4), 317–324. <https://doi.org/10.1176/appi.psy.50.4.317>
- Koblán, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., & Loebel, A. (2020). A non-D2-receptor-binding drug for the treatment of schizophrenia. *New England Journal of Medicine, 382*(16), 1497–1506. <https://doi.org/10.1056/nejmoa1911772>

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*, 353(12), 1209–1223. <https://doi.org/10.1056/nejmoa051688>

LYBALVI (olanzapine and samidorphan) NDA #213378 label, revised 5/2021.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf

LYBALVI (olanzapine/samidorphan), Red Book identifier: 65757-0651-44. (2021). IBM Micromedex RedBook. Retrieved 26 July 2022, from <https://www.micromedexsolutions.com/micromedex2/librarian/>

Macdonald, S., Halliday, J., MacEwan, T., Sharkey, V., Farrington, S., Wall, S., & McCreadie, R. G. (2003). Nithsdale schizophrenia surveys 24: Sexual dysfunction. *British Journal of Psychiatry*, 182(1), 50–56. <https://doi.org/10.1192/bjp.182.1.50>

Mushtaq, S., Khan, S., & Patel, H. (2012). Quetiapine-induced galactorrhea with normal prolactin level in an adult female patient. *Prim Care Companion CNS Disord.*, 14. <https://doi.org/10.4088/pcc.1101284>

NCT01810380. Brexpiprazole in Patients With Acute Schizophrenia. Retrieved 26 July 2022, from <https://clinicaltrials.gov/ct2/show/study/NCT01810380>

Olanzapine, Red Book identifier: 13668-0039-60. (2019). IBM Micromedex RedBook. Retrieved 26 July 2022, from <https://www.micromedexsolutions.com/micromedex2/librarian/>

Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry*, 72(12), 1172–1181. <https://doi.org/10.1001/jamapsychiatry.2015.1737>

Population (United States of America) [interactive chart]. (n.d.). Data Commons. Retrieved 26 July 2022, from https://datacommons.org/tools/timeline#&place=country/USA&statsVar=Count_Person

Potkin, S. G., Kunovac, J., Silverman, B. L., Simmons, A., Jiang, Y., DiPetrillo, L., & McDonnell, D. (2020). Efficacy and safety of a combination of olanzapine and Samidorphan in adult patients with an acute exacerbation of schizophrenia. *The Journal of Clinical Psychiatry*, 81(2). <https://doi.org/10.4088/jcp.19m12769>

Quetiapine fumarate, Red Book identifier: 68180-0450-01. (2018). IBM Micromedex RedBook. Retrieved 26 July 2022, from <https://www.micromedexsolutions.com/micromedex2/librarian/>

- Risperidone, Red Book identifier: 13668-0039-60. (2015). IBM Micromedex RedBook. Retrieved 26 July 2022, from <https://www.micromedexsolutions.com/micromedex2/librarian/>
- RISPERDAL (risperidone) NDA #021444 label, revised 2/2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020272Orig1s083,020588Orig1s071,021444Orig1s057,021346Orig1s061lbl.pdf
- Ritsner, M., Kurs, R., Gibel, A., Ratner, Y., & Endicott, J. (2005). Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-les-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. *Quality of Life Research, 14*(7), 1693–1703. <https://doi.org/10.1007/s11136-005-2816-9>
- Sakson-Obada, O., Chudzikiewicz, P., Pankowski, D., & Jarema, M. (2018). Body Image and Body Experience Disturbances in Schizophrenia: an Attempt to Introduce the Concept of Body Self as a Conceptual Framework. *Curr Psychol., 37*(1), 390–400.
- Schizophrenia. (2022). WHO. Retrieved 26 July 2022, from <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>
- Schizophrenia. (n.d.). NAMI. Retrieved 26 July 2022, from <https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizophrenia>
- Schizophrenia. (n.d.). NIMH. Retrieved 26 July 2022, from <https://www.nimh.nih.gov/health/statistics/schizophrenia>
- Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2018). Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: A 6-month, real-life non-interventional study. *BMC Psychiatry, 18*(1). <https://doi.org/10.1186/s12888-018-1946-x>
- SEROQUEL XR (quetiapine fumarate) NDA #022172 label, revised 1/2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022047s046lbl.pdf
- Shen, J. H. Q., Zhao, Y., Rosenzweig-Lipson, S., Popp, D., Williams, J. B. W., Giller, E., Detke, M. J., & Kane, J. M. (2014). A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in Acute Schizophrenia. *Journal of Psychiatric Research, 53*, 14–22. <https://doi.org/10.1016/j.jpsychires.2014.02.012>
- Torre, D.L. & Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. *Ther Clin Risk Manag, 3*(5), 929-51.
- Yagoda, S., Graham, C., Simmons, A., Arevalo, C., Jiang, Y., & McDonnell, D. (2020). Long-term safety and durability of effect with a combination of olanzapine and Samidorphan in patients with schizophrenia: Results from a 1-year open-label extension study. *CNS Spectrums, 26*(4), 383–392. <https://doi.org/10.1017/s1092852920001376>

ZYPREXA (olanzapine) NDA #020592 label, revised 10/2019.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf